Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer.

Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH.

Clin Cancer Res. 2018 Jan 15;24(2):341-350. doi: 10.1158/1078-0432.CCR-17-1455. Epub 2017 Oct 13.

2.

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.

Nilsson MB, Giri U, Gudikote J, Tang X, Lu W, Tran H, Fan Y, Koo A, Diao L, Tong P, Wang J, Herbst R, Johnson BE, Ryan A, Webster A, Rowe P, Wistuba II, Heymach JV.

Clin Cancer Res. 2016 Apr 15;22(8):1940-50. doi: 10.1158/1078-0432.CCR-15-1994. Epub 2015 Nov 17.

3.

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV.

Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11.

4.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV.

Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.

5.

Frame-disrupting mutations elicit pre-mRNA accumulation independently of frame disruption.

Imam JS, Gudikote JP, Chan WK, Wilkinson MF.

Nucleic Acids Res. 2010 Mar;38(5):1559-74. doi: 10.1093/nar/gkp1115. Epub 2009 Dec 9.

6.

Nonsense codons trigger an RNA partitioning shift.

Bhalla AD, Gudikote JP, Wang J, Chan WK, Chang YF, Olivas OR, Wilkinson MF.

J Biol Chem. 2009 Feb 13;284(7):4062-72. doi: 10.1074/jbc.M805193200. Epub 2008 Dec 17.

7.

An alternative branch of the nonsense-mediated decay pathway.

Chan WK, Huang L, Gudikote JP, Chang YF, Imam JS, MacLean JA 2nd, Wilkinson MF.

EMBO J. 2007 Apr 4;26(7):1820-30. Epub 2007 Mar 15.

8.

RNA splicing promotes translation and RNA surveillance.

Gudikote JP, Imam JS, Garcia RF, Wilkinson MF.

Nat Struct Mol Biol. 2005 Sep;12(9):801-9. Epub 2005 Aug 21.

PMID:
16116435
9.

Boundary-independent polar nonsense-mediated decay.

Wang J, Gudikote JP, Olivas OR, Wilkinson MF.

EMBO Rep. 2002 Mar;3(3):274-9. Epub 2002 Feb 15.

10.
11.

Mitochondrial DNA rearrangements, including partial duplications, occur in young and old rat tissues.

Moore CA, Gudikote J, Van Tuyle GC.

Mutat Res. 1998 Nov 3;421(2):205-17.

PMID:
9852994
12.
13.

Multiple, large deletions in rat mitochondrial DNA: evidence for a major hot spot.

Van Tuyle GC, Gudikote JP, Hurt VR, Miller BB, Moore CA.

Mutat Res. 1996 Jan 17;349(1):95-107.

PMID:
8569796

Supplemental Content

Loading ...
Support Center